Wealth Enhancement Advisory Services LLC Acquires 11,648 Shares of Sanofi $SNY

Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Sanofi (NASDAQ:SNY) by 16.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 82,623 shares of the company’s stock after purchasing an additional 11,648 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Sanofi were worth $3,980,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the stock. Advisory Services Network LLC lifted its position in Sanofi by 1.4% during the third quarter. Advisory Services Network LLC now owns 15,733 shares of the company’s stock valued at $743,000 after purchasing an additional 210 shares during the last quarter. Waterfront Wealth Inc. increased its holdings in shares of Sanofi by 0.4% in the 3rd quarter. Waterfront Wealth Inc. now owns 49,119 shares of the company’s stock worth $2,463,000 after buying an additional 214 shares during the last quarter. HighPoint Advisor Group LLC raised its position in shares of Sanofi by 2.3% during the 3rd quarter. HighPoint Advisor Group LLC now owns 9,923 shares of the company’s stock valued at $468,000 after buying an additional 226 shares in the last quarter. HM Payson & Co. lifted its holdings in shares of Sanofi by 3.4% during the 3rd quarter. HM Payson & Co. now owns 7,248 shares of the company’s stock worth $342,000 after acquiring an additional 235 shares during the last quarter. Finally, Leonard Rickey Investment Advisors P.L.L.C. lifted its holdings in shares of Sanofi by 4.7% during the 3rd quarter. Leonard Rickey Investment Advisors P.L.L.C. now owns 5,333 shares of the company’s stock worth $252,000 after acquiring an additional 238 shares during the last quarter. 14.03% of the stock is currently owned by institutional investors.

Sanofi Price Performance

Shares of NASDAQ:SNY opened at $46.72 on Tuesday. The company has a quick ratio of 0.73, a current ratio of 1.09 and a debt-to-equity ratio of 0.20. The stock has a market cap of $113.95 billion, a PE ratio of 12.98, a PEG ratio of 1.16 and a beta of 0.45. The company’s fifty day moving average is $46.32 and its 200 day moving average is $47.99. Sanofi has a 52 week low of $43.32 and a 52 week high of $55.77.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on SNY shares. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Sanofi in a research note on Friday, January 16th. Weiss Ratings cut Sanofi from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, March 23rd. Bank of America lowered Sanofi from a “buy” rating to a “neutral” rating in a research report on Thursday, February 12th. HSBC reissued a “buy” rating on shares of Sanofi in a report on Wednesday, December 10th. Finally, UBS Group restated a “neutral” rating on shares of Sanofi in a research report on Friday, January 16th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Sanofi presently has a consensus rating of “Hold” and an average target price of $61.50.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.